Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 207

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Anti-GPC3-CAR T Cells Suppress the Growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma

Open access
Jiang, Zhiwu, Jiang, Xiaofeng, Chen, Suimin, Lai, Yunxin, Wei, Xinru, Li, Baiheng, Lin, Simiao, Wang, Suna, Wu, Qiting, Liang, Qiubin, Liu, Qifa, Peng, Muyun, Yu, Fenglei, Weng, Jianyu, Du, Xin, Pei, Duanqing, Liu, Pentao, Yao, Yao, Xue, Ping, Li, Peng · 2017 · Frontiers in Immunology

Abstract

Background: The lack of a general clinic-relevant model for human cancer is a major impediment to the acceleration of novel therapeutic approaches for clinical use. We propose to establish and characterize primary human hepatocellular carcinoma (HCC) xenografts that can be used to evaluate the cytotoxicity of adoptive chimeric antigen receptor (CAR) T cells and accelerate the clinical translation of CAR T cells used in HCC. Methods: Primary HCCs were used to establish the xenografts. The morphology, immunological markers, and gene expression characteristics of xenografts were detected and compared to those of the corresponding primary tumors. CAR T cells were adoptively transplanted into patient-derived xenograft (PDX) models of HCC. The cytotoxicity of CAR T cells in vivo was evaluated. Results: PDX1, PDX2, and PDX3 were established using primary tumors from three individual HCC patients. All three PDX maintained original tumor characteristics in their morphology, immunological markers, and gene expression. Tumors in PDX1 grew relatively slower than that in PDX2 and PDX3. GPC3-CAR T cells efficiently suppressed tumor growth in PDX3 and impressively eradicated tumor cells from PDX1 and PDX2, in which GPC3 proteins were highly expressed. Conclusion: GPC3-CAR T cells were capable of effectively eliminating tumors in PDX model of HCC. Therefore, GPC3-CAR T cell therapy is a promising candidate for HCC treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2016.00690

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 27

  1. Sharma, 2015, CD4+CD25+CD127low regulatory T cells play predominant anti-tumor suppressive role in hepatitis B virus associated hepatocellular carcinoma, Front Immunol, 6, 49, 10.3389/fimmu.2015.00049 · DOI
  2. Page, 2014, Hepatocellular carcinoma: diagnosis, management, and prognosis, Surg Oncol Clin N Am, 23, 289, 10.1016/j.soc.2013.10.006 · DOI
  3. Jayachandran, 2016, Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinoma, J Hematol Oncol, 9, 74, 10.1186/s13045-016-0307-9 · DOI · Paper page
  4. Clavien, 2007, Strategies for safer liver surgery and partial liver transplantation, N Engl J Med, 356, 1545, 10.1056/NEJMra065156 · DOI · Paper page
  5. Waghray, 2015, Hepatocellular carcinoma: from diagnosis to treatment, World J Hepatol, 7, 1020, 10.4254/wjh.v7.i8.1020 · DOI · Paper page
  6. Toyoda, 2004, Changes in the characteristics and survival rate of hepatocellular carcinoma from 1976 to 2000: analysis of 1365 patients in a single institution in Japan, Cancer, 100, 2415, 10.1002/cncr.20289 · DOI
  7. Lee, 2012, Analysis of prognostic factors and 5-year survival rate in patients with hepatocellular carcinoma: a single-center experience, Korean J Hepatol, 18, 48, 10.3350/kjhep.2012.18.1.48 · doi:10.3350/kjhep.2012.18.1.48
  8. Jin, 2010, Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review, Clin Transl Oncol, 12, 473, 10.1007/s12094-010-0540-6 · DOI · Paper page
  9. Bissig-Choisat, 2016, Novel patient-derived xenograft and cell line models for therapeutic testing of pediatric liver cancer, J Hepatol, 65, 325, 10.1016/j.jhep.2016.04.009 · DOI
  10. Huynh, 2006, Xenografts of human hepatocellular carcinoma: a useful model for testing drugs, Clin Cancer Res, 12, 4306, 10.1158/1078-0432.CCR-05-2568 · DOI
  11. Dargel, 2015, T cells engineered to express a T-cell receptor specific for glypican-3 to recognize and kill hepatoma cells in vitro and in mice, Gastroenterology, 149, 1042, 10.1053/j.gastro.2015.05.055 · DOI
  12. Gao, 2014, Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma, Clin Cancer Res, 20, 6418, 10.1158/1078-0432.CCR-14-1170 · DOI · Paper page
  13. Wenpeng, 2016, Redirecting T cells to glypican-3 with 4-1BB zeta chimeric antigen receptors results in Th1 polarization and potent antitumor activity, Hum Gene Ther, 10.1089/hum.2016.025 · DOI
  14. Ye, 2015, Quantitative evaluation of the immunodeficiency of a mouse strain by tumor engraftments, J Hematol Oncol, 8, 59, 10.1186/s13045-015-0156-y · DOI
  15. Jiang, 2016, Heterogeneity of CD34 and CD38 expression in acute B lymphoblastic leukemia cells is reversible and not hierarchically organized, J Hematol Oncol, 9, 94, 10.1186/s13045-016-0310-1 · doi:10.1186/s13045-016-0310-1
  16. Xiao, 2015, Loss of Angiopoietin-like 7 diminishes the regeneration capacity of hematopoietic stem and progenitor cells, J Hematol Oncol, 8, 7, 10.1186/s13045-014-0102-4 · DOI
  17. Nakano, 2007, Anti-Glypican 3 Antibody
  18. Venepalli, 2013, Targeting the HGF-cMET axis in hepatocellular carcinoma, Int J Hepatol, 2013, 341636, 10.1155/2013/341636 · DOI
  19. Nault, 2013, A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection, Gastroenterology, 145, 176, 10.1053/j.gastro.2013.03.051 · DOI · Paper page
  20. Jeannin, 1999, Human effector memory T cells express CD86: a functional role in naive T cell priming, J Immunol, 162, 2044, 10.4049/jimmunol.162.4.2044 · DOI
  21. Long, 2015, 4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors, Nat Med, 21, 581, 10.1038/nm.3838 · DOI · Paper page
  22. Xin, 2014, Establishment and characterization of 7 novel hepatocellular carcinoma cell lines from patient-derived tumor xenografts, PLoS One, 9, e85308, 10.1371/journal.pone.0085308 · DOI
  23. Zhang, 2002, Polymorphisms in cyclin D1 gene and hepatocellular carcinoma, Mol Carcinog, 33, 125, 10.1002/mc.10028.abs · doi:10.1002/mc.10028.abs
  24. Domaica, 2009, Tumour-experienced T cells promote NK cell activity through trogocytosis of NKG2D and NKp46 ligands, EMBO Rep, 10, 908, 10.1038/embor.2009.92 · DOI
  25. Han, 2013, Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges, J Hematol Oncol, 6, 47, 10.1186/1756-8722-6-47 · DOI
  26. John, 2013, Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells, Clin Cancer Res, 19, 5636, 10.1158/1078-0432.CCR-13-0458 · DOI · Paper page
  27. Moon, 2014, Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors, Clin Cancer Res, 20, 4262, 10.1158/1078-0432.CCR-13-2627 · DOI · Paper page

Cited by

See all 207

Metadata

Authors
Jiang, Z., Jiang, X., Chen, S., Lai, Y., Wei, X., Li, B., Lin, S., Wang, S., Wu, Q., Liang, Q., Liu, Q., Peng, M., Yu, F., Weng, J., Du, X., Pei, D., Liu, P., Yao, Y., Xue, P., & Li, P.
Venue
Frontiers in Immunology
Published
2017-01-11
Volume
7
Pages
690-690
ISSN
1664-3224 (ISSN-L)
OpenAlex
W2570331434
Cited by
207
References
5
FWCI
7.76
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.